

SEQUENCE LISTING

<110> F. Hoffmann-La Roche AG

<120> Enzymatic Antibody Processing

<130> 26225 WO

<150> EP 09166845.9

<151> 2009-07-30

<160> 2

<170> PatentIn version 3.5

<210> 1

<211> 1113

<212> DNA

<213> Artificial Sequence

<220>

<223> nucleic acid sequence of the human mutated IL15/Fc with CD5 leader peptide

<400> 1

atgcccatgg ggtctctgca accgctggcc accttgtagc tgctggggat gctgggtcgct	60
tcctgcctcg gaaactgggt gaatgtaata agtgatttga aaaaaattga agatcttatt	120
caatctatgc atattgatgc tactttatat acggaaagtg atgttcaccc cagttgcaaa	180
gtaacagcaa tgaagtgctt tctcttgag ttacaagtta tttcacttga gtccggagat	240
gcaagtattc atgatacagt agaaaatctg atcatcctag caaacaacag tttgtcttct	300
aatgggaatg taacagaatc tggatgcaaa gaatgtgagg aactggagga aaaaaatatt	360
aaagaatttt tggacagttt tgtacatatt gtcgacatgt tcatcaacac ttcggatccc	420
aaatctgctg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga	480
ccgtcagttc tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggaccct	540
gaggtcacgt gcgtgggtgg ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg	600
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgaggagga gcagtacaac	660
agcacgtacc gtgtgggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag	720
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc	780
aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag	840
ctgaccaaga accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc	900
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgctg	960

ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg 1020  
cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg 1080  
cagaagagcc tctccctgtc tccgggtaaa tga 1113

<210> 2

<211> 370

<212> PRT

<213> Artificial Sequence

<220>

<223> amino acid sequence of the human mutated IL15/Fc with CD5 leader peptide

<400> 2

Met Pro Met Gly Ser Leu Gln Pro Leu Ala Thr Leu Tyr Leu Leu Gly  
1 5 10 15

Met Leu Val Ala Ser Cys Leu Gly Asn Trp Val Asn Val Ile Ser Asp  
20 25 30

Leu Lys Lys Ile Glu Asp Leu Ile Gln Ser Met His Ile Asp Ala Thr  
35 40 45

Leu Tyr Thr Glu Ser Asp Val His Pro Ser Cys Lys Val Thr Ala Met  
50 55 60

Lys Cys Phe Leu Leu Glu Leu Gln Val Ile Ser Leu Glu Ser Gly Asp  
65 70 75 80

Ala Ser Ile His Asp Thr Val Glu Asn Leu Ile Ile Leu Ala Asn Asn  
85 90 95

Ser Leu Ser Ser Asn Gly Asn Val Thr Glu Ser Gly Cys Lys Glu Cys  
100 105 110

Glu Glu Leu Glu Glu Lys Asn Ile Lys Glu Phe Leu Asp Ser Phe Val  
115 120 125

His Ile Val Asp Met Phe Ile Asn Thr Ser Asp Pro Lys Ser Ala Asp  
130 135 140

Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly  
145 150 155 160

Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile

165								170					175				
Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu		
			180				185						190				
Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His		
		195				200						205					
Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg		
		210				215						220					
Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys		
225					230						235			240			
Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu		
				245						250			255				
Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr		
			260						265						270		
Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu		
		275						280						285			
Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp		
		290			295						300						
Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val		
305					310						315			320			
Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp		
				325						330						335	
Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His		
			340						345						350		
Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser	Pro		
		355						360						365			
Gly	Lys																
370																	